Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It's typically caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke.
The global market for COPD Medication was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for COPD Medication, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of COPD Medication by region & country, by Type, and by Application.
The COPD Medication market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COPD Medication.
麻豆原创 Segmentation
By Company
Roche
Novartis
GSK
Teva
AstraZeneca
Boehringer Ingelheim
Nephron Pharmaceuticals
Segment by Type:
Short-Acting Bronchodilator
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Combination Drugs
Segment by Application
Hospital
Clinic
Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of COPD Medication manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of COPD Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of COPD Medication in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 COPD Medication Product Introduction
1.2 Global COPD Medication 麻豆原创 Size Forecast
1.3 COPD Medication 麻豆原创 Trends & Drivers
1.3.1 COPD Medication Industry Trends
1.3.2 COPD Medication 麻豆原创 Drivers & Opportunity
1.3.3 COPD Medication 麻豆原创 Challenges
1.3.4 COPD Medication 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global COPD Medication Players Revenue Ranking (2023)
2.2 Global COPD Medication Revenue by Company (2019-2024)
2.3 Key Companies COPD Medication Manufacturing Base Distribution and Headquarters
2.4 Key Companies COPD Medication Product Offered
2.5 Key Companies Time to Begin Mass Production of COPD Medication
2.6 COPD Medication 麻豆原创 Competitive Analysis
2.6.1 COPD Medication 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by COPD Medication Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COPD Medication as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Short-Acting Bronchodilator
3.1.2 Corticosteroids
3.1.3 Methylxanthines
3.1.4 Long-Acting Bronchodilators
3.1.5 Combination Drugs
3.2 Global COPD Medication Sales Value by Type
3.2.1 Global COPD Medication Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global COPD Medication Sales Value, by Type (2019-2030)
3.2.3 Global COPD Medication Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Pharmacy
4.1.4 Online Pharmacy
4.2 Global COPD Medication Sales Value by Application
4.2.1 Global COPD Medication Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global COPD Medication Sales Value, by Application (2019-2030)
4.2.3 Global COPD Medication Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global COPD Medication Sales Value by Region
5.1.1 Global COPD Medication Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global COPD Medication Sales Value by Region (2019-2024)
5.1.3 Global COPD Medication Sales Value by Region (2025-2030)
5.1.4 Global COPD Medication Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America COPD Medication Sales Value, 2019-2030
5.2.2 North America COPD Medication Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe COPD Medication Sales Value, 2019-2030
5.3.2 Europe COPD Medication Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific COPD Medication Sales Value, 2019-2030
5.4.2 Asia Pacific COPD Medication Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America COPD Medication Sales Value, 2019-2030
5.5.2 South America COPD Medication Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa COPD Medication Sales Value, 2019-2030
5.6.2 Middle East & Africa COPD Medication Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions COPD Medication Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions COPD Medication Sales Value
6.3 United States
6.3.1 United States COPD Medication Sales Value, 2019-2030
6.3.2 United States COPD Medication Sales Value by Type (%), 2023 VS 2030
6.3.3 United States COPD Medication Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe COPD Medication Sales Value, 2019-2030
6.4.2 Europe COPD Medication Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe COPD Medication Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China COPD Medication Sales Value, 2019-2030
6.5.2 China COPD Medication Sales Value by Type (%), 2023 VS 2030
6.5.3 China COPD Medication Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan COPD Medication Sales Value, 2019-2030
6.6.2 Japan COPD Medication Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan COPD Medication Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea COPD Medication Sales Value, 2019-2030
6.7.2 South Korea COPD Medication Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea COPD Medication Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia COPD Medication Sales Value, 2019-2030
6.8.2 Southeast Asia COPD Medication Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia COPD Medication Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India COPD Medication Sales Value, 2019-2030
6.9.2 India COPD Medication Sales Value by Type (%), 2023 VS 2030
6.9.3 India COPD Medication Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche COPD Medication Products, Services and Solutions
7.1.4 Roche COPD Medication Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Novartis
7.2.1 Novartis Profile
7.2.2 Novartis Main Business
7.2.3 Novartis COPD Medication Products, Services and Solutions
7.2.4 Novartis COPD Medication Revenue (US$ Million) & (2019-2024)
7.2.5 Novartis Recent Developments
7.3 GSK
7.3.1 GSK Profile
7.3.2 GSK Main Business
7.3.3 GSK COPD Medication Products, Services and Solutions
7.3.4 GSK COPD Medication Revenue (US$ Million) & (2019-2024)
7.3.5 Teva Recent Developments
7.4 Teva
7.4.1 Teva Profile
7.4.2 Teva Main Business
7.4.3 Teva COPD Medication Products, Services and Solutions
7.4.4 Teva COPD Medication Revenue (US$ Million) & (2019-2024)
7.4.5 Teva Recent Developments
7.5 AstraZeneca
7.5.1 AstraZeneca Profile
7.5.2 AstraZeneca Main Business
7.5.3 AstraZeneca COPD Medication Products, Services and Solutions
7.5.4 AstraZeneca COPD Medication Revenue (US$ Million) & (2019-2024)
7.5.5 AstraZeneca Recent Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Profile
7.6.2 Boehringer Ingelheim Main Business
7.6.3 Boehringer Ingelheim COPD Medication Products, Services and Solutions
7.6.4 Boehringer Ingelheim COPD Medication Revenue (US$ Million) & (2019-2024)
7.6.5 Boehringer Ingelheim Recent Developments
7.7 Nephron Pharmaceuticals
7.7.1 Nephron Pharmaceuticals Profile
7.7.2 Nephron Pharmaceuticals Main Business
7.7.3 Nephron Pharmaceuticals COPD Medication Products, Services and Solutions
7.7.4 Nephron Pharmaceuticals COPD Medication Revenue (US$ Million) & (2019-2024)
7.7.5 Nephron Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 COPD Medication Industrial Chain
8.2 COPD Medication Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 COPD Medication Sales Model
8.5.2 Sales Channel
8.5.3 COPD Medication Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Roche
Novartis
GSK
Teva
AstraZeneca
Boehringer Ingelheim
Nephron Pharmaceuticals
听
听
*If Applicable.